HRP20160540T1 - Sol i solvati jednog derivata tetrahidroizokinolina - Google Patents
Sol i solvati jednog derivata tetrahidroizokinolina Download PDFInfo
- Publication number
- HRP20160540T1 HRP20160540T1 HRP20160540TT HRP20160540T HRP20160540T1 HR P20160540 T1 HRP20160540 T1 HR P20160540T1 HR P20160540T T HRP20160540T T HR P20160540TT HR P20160540 T HRP20160540 T HR P20160540T HR P20160540 T1 HRP20160540 T1 HR P20160540T1
- Authority
- HR
- Croatia
- Prior art keywords
- solvate
- degrees
- sodium salt
- crystalline
- isoquinoline
- Prior art date
Links
- 239000012453 solvate Substances 0.000 title claims 36
- 150000003839 salts Chemical class 0.000 title 1
- 125000003039 tetrahydroisoquinolinyl group Chemical class C1(NCCC2=CC=CC=C12)* 0.000 title 1
- 159000000000 sodium salts Chemical class 0.000 claims 12
- 238000000034 method Methods 0.000 claims 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 6
- 238000000634 powder X-ray diffraction Methods 0.000 claims 6
- GHBCIXGRCZIPNQ-MHZLTWQESA-N (3s)-2-(2,2-diphenylacetyl)-6-methoxy-5-phenylmethoxy-3,4-dihydro-1h-isoquinoline-3-carboxylic acid Chemical compound C([C@H](N(CC1=CC=C2OC)C(=O)C(C=3C=CC=CC=3)C=3C=CC=CC=3)C(O)=O)C1=C2OCC1=CC=CC=C1 GHBCIXGRCZIPNQ-MHZLTWQESA-N 0.000 claims 5
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims 4
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 claims 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 4
- 239000007787 solid Substances 0.000 claims 3
- 230000001476 alcoholic effect Effects 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- -1 sodium alkoxide Chemical class 0.000 claims 2
- NASFKTWZWDYFER-UHFFFAOYSA-N sodium;hydrate Chemical compound O.[Na] NASFKTWZWDYFER-UHFFFAOYSA-N 0.000 claims 2
- ACGYQXYBZPWBLS-HNNXBMFYSA-N (3s)-6-methoxy-5-phenylmethoxy-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid Chemical compound C([C@H](NCC1=CC=C2OC)C(O)=O)C1=C2OCC1=CC=CC=C1 ACGYQXYBZPWBLS-HNNXBMFYSA-N 0.000 claims 1
- JRVORWMACMEOAD-UHFFFAOYSA-N [N].C1=NC=CC2=CC=CC=C21 Chemical group [N].C1=NC=CC2=CC=CC=C21 JRVORWMACMEOAD-UHFFFAOYSA-N 0.000 claims 1
- 230000010933 acylation Effects 0.000 claims 1
- 238000005917 acylation reaction Methods 0.000 claims 1
- 230000005540 biological transmission Effects 0.000 claims 1
- 150000003950 cyclic amides Chemical class 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000001035 drying Methods 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 238000001953 recrystallisation Methods 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36636710P | 2010-07-21 | 2010-07-21 | |
| EP11740973.0A EP2595960B1 (en) | 2010-07-21 | 2011-07-21 | Salt and solvates of a tetrahydroisoquinoline derivative |
| PCT/GB2011/001096 WO2012010843A1 (en) | 2010-07-21 | 2011-07-21 | Salt and solvates of a tetrahydroisoquinoline derivative |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20160540T1 true HRP20160540T1 (hr) | 2016-06-17 |
Family
ID=44386640
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20160540TT HRP20160540T1 (hr) | 2010-07-21 | 2016-05-20 | Sol i solvati jednog derivata tetrahidroizokinolina |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US8614227B2 (zh) |
| EP (2) | EP2595960B1 (zh) |
| JP (3) | JP5948326B2 (zh) |
| CN (2) | CN103003244B (zh) |
| AU (3) | AU2011281381B2 (zh) |
| CA (1) | CA2803699C (zh) |
| DK (1) | DK2595960T3 (zh) |
| ES (1) | ES2570135T3 (zh) |
| HK (1) | HK1224290A1 (zh) |
| HR (1) | HRP20160540T1 (zh) |
| HU (1) | HUE028620T2 (zh) |
| ME (1) | ME02407B (zh) |
| NZ (2) | NZ605444A (zh) |
| PL (1) | PL2595960T3 (zh) |
| PT (1) | PT2595960E (zh) |
| SI (1) | SI2595960T1 (zh) |
| SM (1) | SMT201600171B (zh) |
| WO (1) | WO2012010843A1 (zh) |
| ZA (1) | ZA201300169B (zh) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2595960B1 (en) * | 2010-07-21 | 2016-02-24 | Novartis AG | Salt and solvates of a tetrahydroisoquinoline derivative |
| US9320530B2 (en) * | 2013-03-13 | 2016-04-26 | The Spectranetics Corporation | Assisted cutting balloon |
| PL3019477T3 (pl) * | 2013-07-08 | 2021-11-22 | Novartis Ag | Związki heterocykliczne i sposoby ich stosowania |
| JP6667551B2 (ja) | 2015-01-13 | 2020-03-18 | ノバルティス アーゲー | アンジオテンシンｉｉ２型拮抗薬としてのピロリジン誘導体 |
| ES2898635T3 (es) | 2015-03-12 | 2022-03-08 | Novartis Ag | Compuestos heterocíclicos y métodos para su uso |
| CN106478502B (zh) * | 2015-08-29 | 2021-04-27 | 上海翰森生物医药科技有限公司 | 1,2,3,4-四氢异喹啉衍生物、其制备方法和应用 |
| EP3475261A1 (en) | 2016-06-27 | 2019-05-01 | ratiopharm GmbH | Crystalline calcium salt of (s)-2-(diphenylacetyl)-1,2,3,4-tetrahydro-6-methoxy-5-(phenylmethoxy)-3-isoquinoline carboxylic acid |
| JP2019514862A (ja) * | 2017-03-23 | 2019-06-06 | ノバルティス アーゲー | （ｓ）−２−（ジフェニルアセチル）−１，２，３，４−テトラヒドロ−６−メトキシ−５−（フェニルメトキシ）−３−イソキノリンカルボン酸ナトリウムの無水結晶形 |
| WO2018224037A1 (zh) * | 2017-06-09 | 2018-12-13 | 南京明德新药研发股份有限公司 | 作为at2r受体拮抗剂的羧酸衍生物 |
| WO2020012266A1 (en) | 2018-07-12 | 2020-01-16 | Novartis Ag | Biocatalytic synthesis of olodanrigan (ema401) from 3-(2-(benzyloxy)-3-methoxyphenyl)propenoic acid with phenylalanine ammonia lyase |
| CN112672989A (zh) * | 2018-07-12 | 2021-04-16 | 科德克希思公司 | 工程化苯丙氨酸氨裂合酶多肽 |
| CN111620816B (zh) * | 2020-05-27 | 2023-06-02 | 上海赛默罗生物科技有限公司 | 螺桨烷类衍生物、其制备方法、药物组合物和用途 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5246943A (en) * | 1992-05-19 | 1993-09-21 | Warner-Lambert Company | Substituted 1,2,3,4-tetahydroisoquinolines with angiotensin II receptor antagonist properties |
| US5236934A (en) | 1992-08-26 | 1993-08-17 | E. I. Du Pont De Nemours And Company | 1,2,3,4-tetrahydroisoquinolines useful in the treatment of CNS disorders |
| JP2002504498A (ja) * | 1998-02-25 | 2002-02-12 | メルク エンド カムパニー インコーポレーテッド | アンギオテンシンｉｉ受容体拮抗薬を用いてｑｔ分散を低下させる、または、ｑｔ分散の進行を阻害する方法 |
| JP4966202B2 (ja) * | 2004-12-24 | 2012-07-04 | スピニフェクス ファーマシューティカルズ ピーティーワイ リミテッド | 治療または予防のための方法 |
| JP5230595B2 (ja) | 2006-03-20 | 2013-07-10 | スピニフェクス ファーマシューティカルズ ピーティーワイ リミテッド | 炎症性疼痛の治療または予防の方法 |
| NZ601383A (en) * | 2010-01-19 | 2014-07-25 | Spinifex Pharm Pty Ltd | Methods and compositions for improved nerve conduction velocity |
| EP2595960B1 (en) * | 2010-07-21 | 2016-02-24 | Novartis AG | Salt and solvates of a tetrahydroisoquinoline derivative |
-
2011
- 2011-07-21 EP EP11740973.0A patent/EP2595960B1/en active Active
- 2011-07-21 SI SI201130804A patent/SI2595960T1/sl unknown
- 2011-07-21 CN CN201180035468.9A patent/CN103003244B/zh not_active Expired - Fee Related
- 2011-07-21 JP JP2013520203A patent/JP5948326B2/ja not_active Expired - Fee Related
- 2011-07-21 PT PT117409730T patent/PT2595960E/pt unknown
- 2011-07-21 US US13/187,882 patent/US8614227B2/en not_active Expired - Fee Related
- 2011-07-21 HU HUE11740973A patent/HUE028620T2/en unknown
- 2011-07-21 NZ NZ605444A patent/NZ605444A/en not_active IP Right Cessation
- 2011-07-21 ES ES11740973T patent/ES2570135T3/es active Active
- 2011-07-21 EP EP15200360.4A patent/EP3081557A1/en not_active Withdrawn
- 2011-07-21 DK DK11740973.0T patent/DK2595960T3/en active
- 2011-07-21 ME MEP-2016-98A patent/ME02407B/me unknown
- 2011-07-21 CA CA2803699A patent/CA2803699C/en not_active Expired - Fee Related
- 2011-07-21 WO PCT/GB2011/001096 patent/WO2012010843A1/en active Application Filing
- 2011-07-21 PL PL11740973.0T patent/PL2595960T3/pl unknown
- 2011-07-21 AU AU2011281381A patent/AU2011281381B2/en not_active Ceased
- 2011-07-21 NZ NZ708529A patent/NZ708529A/en not_active IP Right Cessation
- 2011-07-21 CN CN201610152658.3A patent/CN105777636A/zh active Pending
-
2013
- 2013-01-08 ZA ZA2013/00169A patent/ZA201300169B/en unknown
- 2013-07-03 HK HK16112556.3A patent/HK1224290A1/zh unknown
- 2013-11-18 US US14/083,391 patent/US8927575B2/en not_active Expired - Fee Related
-
2014
- 2014-12-17 US US14/573,774 patent/US9162985B2/en not_active Expired - Fee Related
-
2015
- 2015-10-06 AU AU2015238774A patent/AU2015238774A1/en not_active Abandoned
-
2016
- 2016-04-11 JP JP2016078656A patent/JP2016164178A/ja active Pending
- 2016-05-20 HR HRP20160540TT patent/HRP20160540T1/hr unknown
- 2016-06-15 SM SM201600171T patent/SMT201600171B/it unknown
-
2017
- 2017-05-15 AU AU2017203236A patent/AU2017203236A1/en not_active Abandoned
- 2017-08-14 JP JP2017156436A patent/JP2017214415A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20160540T1 (hr) | Sol i solvati jednog derivata tetrahidroizokinolina | |
| HRP20160030T1 (hr) | Derivati 6,7-dihidro-pirazolo[1,5-a]pirazin-4-ilamina koji su korisni kao inhibitori beta-sekretaze (bace) | |
| HRP20140666T1 (hr) | Kristalni oblici derivata 2-tiazolil-4-kinolinil-oksi, snažnog hcv-inhibitora | |
| WO2021147236A9 (zh) | 取代氨基丙酸酯类化合物在治疗SARS-CoV-2感染中的应用 | |
| HRP20150702T1 (hr) | Supstituirani 4-aril-1,4-dihidro-1,6-naftiridinamidi i njihova uporaba | |
| WO2020016749A3 (en) | Chemical process for preparing phenylpiperidinyl indole derivatives | |
| WO2013179300A2 (en) | A process for the preparation of vildagliptin and its intermediate thereof | |
| FI3057962T3 (fi) | Hydrokloridisuolamuoto ezh2-estoon | |
| WO2009125434A3 (en) | Oxime derivatives, process for their preparation, pharmaceutical composition containing the same and medicinal use thereof | |
| JP2011512361A5 (zh) | ||
| JP2014506907A5 (zh) | ||
| AU2015221439B2 (en) | Crystalline 6,7-unsaturated-7-carbamoyl morphinane derivative, and method for producing same | |
| WO2007099553A3 (en) | 1,3-dioxane carboxylic acids | |
| JPH02289583A (ja) | ５―アルキルキノロンカルボン酸類 | |
| WO2010007316A3 (fr) | NOUVEAUX DERIVES TRIAZOLO(4,3-a)PYRIDINE,LEUR PROCEDE DE PREPARATION,LEUR APPLICATION A TITRE DE MEDICAMENTS,COMPOSITIONS PHARMACEUTIQUES ET NOUVELLE UTILISATION NOTAMMENT COMME INHIBITEURS DE MET | |
| DE69333223T2 (de) | Bicyclische Aminderivate | |
| RU2011105878A (ru) | Способ получения магниевой соли эзомепразола в стабильной форме | |
| WO2010011811A3 (en) | 3-(phenoxyphenylmethyl)pyrrolidine compounds | |
| AU2010271746B2 (en) | 2-[[[2-[(hydroxyacetyl)amino]-4-pyridinyl]methyl]thio]-N-[4-(trifluoromethoxy) phenyl]-3-pyridinecarboxamide benzene- sulfonate, crystals of same, polymorphs thereof, and processes for production thereof | |
| JP2005513144A (ja) | ２−メチル−４−（４−メチル−１−ピペラジニル）−１０Ｈ−チエノ［２，３−ｂ］［１，５］ベンゾジアゼピンの結晶形Ｉ | |
| AU2011363636B2 (en) | Process for the production of a pemetrexed salt | |
| WO2011008666A3 (en) | 3-phenoxymethylpyrrolidine compounds | |
| WO2007031845A3 (en) | Polymorphic forms of (s)-omeprazole magnesium salts and processes for their preparation | |
| AR063469A1 (es) | Formas polimorficas de ácido (3r,5r)-7-[2-(4-fluorofenil)-5-isopropil-3-fenil-4-[(4-hidroximetilfenilamino)carbonil]-pirrol-1-il]-3, 5-dihidroxi-heptanoico, sal hemicalcio, metodos de preparacion de las mismas, una composicion farmaceutica que las comprende y su uso en el tratamiento de enfermedades | |
| WO2020257733A1 (en) | Histone demethylase inhibitors for treating cancers |